证券日报网讯 12月5日晚间，金埔园林发布公告称，公司无逾期对外担保、无违规担保等情况。 （文章来源：证券日报） ...

| 证券代码：301098 | 证券简称：金埔园林 | 公告编号：2025-143 | | --- | --- | --- | | 债券代码：123198 | 债券简称：金埔转债 | | 金埔园林股份有限公司 关于对外担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 金埔园林股份有限公司（以下简称"金埔园林"、"公司"）于2025年4月18日 召开第五届董事会第二十一次会议、第五届监事会第十二次会议，分别审议通过 了《关于预计对外担保额度的议案》，同意公司与合并报表范围内子公司拟向银 行及其它机构申请授信及贷款时，互相提供担保，担保金额上限为48,000万元。 担保范围包括但不限于债权本金及按主合同约定计收的全部利息。担保方式包括 但不限于保证担保、资产抵押、质押等。在上述额度内，公司可根据实际经营需 要对公司与公司合并报表范围内的子公司之间及子公司相互之间的担保金额进 行调剂，不需要单独进行审批。本次对外担保额度授权期限为公司2024年年度股 东大会审议通过之日起至2025年年度股东大会召开日止。具体内容详见公司于 2025年 ...

证券日报网讯12月2日，金埔园林（301098）在互动平台回答投资者提问时表示，截至2025年11月28日 公司合并普通账户和融资融券信用账户的在册股东总数为10600户。 ...

债券受托管理人： 股票简称：金埔园林 股票代码：301098 债券简称：金埔转债 债券代码：123198 长江证券承销保荐有限公司 关于金埔园林股份有限公司向不特定对象 发行可转换公司债券的临时受托管理事务 报告 金埔园林股份有限公司向不特定对象发行可转换公司债券 2025 年度第 6 次临时受托管理事务报告 中国（上海）自由贸易试验区世纪大道1198号28层 2025 年 12 月 金埔园林股份有限公司向不特定对象发行可转换公司债券 2025 年度第 6 次临时受托管理事务报告 声 明 长江证券承销保荐有限公司（以下简称"长江保荐"、"保荐人"或"受托管 理人"）编制本报告的内容及信息均来源于发行人相关信息披露文件、金埔园林 股份有限公司（以下简称"金埔园林"、"发行人"或"公司"）提供的证明文件 及第三方中介机构出具的专业意见。长江保荐对报告中所包含的相关引述内容和 信息未进行独立验证，也不就该等引述内容和信息的真实性、准确性和完整性做 出任何保证或承担任何责任。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为长江保荐所作的承诺 或 ...

Group 1: Storage Market Dynamics - The storage spot market is experiencing strong demand, leading to continued price increases for finished products, despite high prices [1] - Customers with low inventory levels are gradually accepting new pricing agreements, providing manufacturers with confidence to raise prices [1] - The significant price increases are affecting retail markets, with online and offline retailers raising prices for memory modules and SSDs, potentially reducing consumer purchasing willingness [1] Group 2: DRAM Industry Forecast - According to TrendForce, the DRAM industry revenue is expected to grow by 30.9% quarter-on-quarter in Q3 2025, reaching $41.4 billion due to rising contract prices and increased shipment volumes [1] - The fourth quarter is anticipated to see a significant increase in contract prices, with conventional DRAM prices expected to rise by 45%-50% [1] - The overall contract prices for conventional DRAM and HBM combined are projected to increase by 50%-55% [1] Group 3: Medical Device Market Growth - The Chinese medical device market is projected to reach ¥1.22 trillion by 2025, with over 33,000 production enterprises expected by the end of 2024, marking a 27.8% increase from the end of the 13th Five-Year Plan [2] - The industry is transitioning from "catching up" to "running alongside and leading," supporting the "Healthy China" strategy [2] Group 4: Flu Season Impact on Pharmaceuticals - The flu season has started early in China, with a 237% increase in sales of Oseltamivir over the past week, and a 180% increase for Maviral [2] - The peak of the flu season is expected between mid-December and early January [2] Group 5: Cinema Industry Growth - As of October 2023, China has added 233 cinemas and 1,588 screens, totaling 15,438 operating cinemas and 92,556 screens nationwide [3] - County-level cinemas account for 21.06% of the total, while town cinemas make up 18.01% [3] Group 6: Innovations in Medical Technology - Novo Nordisk's Kyinsu, the world's first weekly insulin and GLP-1 receptor agonist combination, has been approved in the EU for adults with type 2 diabetes [3] - This innovation represents a significant advancement in diabetes treatment options [3] Group 7: Corporate Developments - Allianz Partners plans to lay off 1,500 to 1,800 employees over the next 12-18 months, primarily in call center roles due to automation [5] - Novartis announced plans to cut up to 550 jobs in Switzerland by the end of 2027 as part of production adjustments [5]

Group 1 - Aolide plans to raise no more than 300 million yuan through a simplified procedure for issuing shares to specific targets, with net proceeds allocated to the production base project for OLED display core materials and to supplement working capital [1] - Wanbang's subsidiary has obtained a 10-year exclusive agency for sildenafil oral suspension, which is suitable for patients with swallowing difficulties [2] - Titan Technology and its affiliate plan to jointly invest in increasing capital for its subsidiary, Micro Detection, raising its registered capital from 10 million yuan to 50 million yuan [3] Group 2 - Jindike will not issue new batches of quadrivalent influenza virus split vaccine this year, having produced approximately 1.56 million doses [4] - Aladdin intends to purchase 35% equity of Youke for 61.25 million yuan, funded by its own or raised capital [5] - Gujia Home's application for a private placement of A-shares has been approved by the Shanghai Stock Exchange [7] Group 3 - Honghe Technology's application for a private placement of A-shares has been approved by the China Securities Regulatory Commission [9] - Guangdian Yuntong has won contracts totaling 308 million yuan for the construction of an artificial intelligence application pilot base [10] - Shanghai Mechanical plans to repurchase B-shares worth no more than 278 million yuan [11] Group 4 - Weiling Co. is planning a change of control, with shares representing 7.76% of the total being transferred [14] - Jiugang Hongxing intends to invest 200 million yuan to establish a wholly-owned subsidiary focusing on high-quality special steel materials [16] - Zhongjian Technology has submitted an application for H-share listing [17] Group 5 - Sainuo Medical has received registration approval for its coronary product in Pakistan [18] - Huafeng Aluminum plans to acquire 100% equity of Huafeng Puen for 100 million yuan [20] - Fuda Co. intends to establish a wholly-owned subsidiary with an investment of 30 million yuan [22] Group 6 - Su Yan Jingshen's application for a private placement of shares has been approved by the Shanghai Stock Exchange [24] - Zhongchuang Co. has set the inquiry transfer price at 25.75 yuan per share [25] - Jinpu Garden has had a lawsuit involving 26.557 million yuan accepted by the court [29] Group 7 - ICBC has approved the appointment of Zhao Guid as vice president [30] - Betta Pharmaceuticals has had its drug registration application for ensartinib accepted [32] - Times New Materials plans to invest 6 million euros to establish a wholly-owned subsidiary in Serbia [34] Group 8 - China State Construction has appointed Chen Yong as vice president [36] - Dayang Electric plans to invest 10 million yuan to establish an industrial fund [38] - Advanced Digital has appointed Liu Zhigang as deputy general manager [39] Group 9 - Tianqi Co. plans to transfer 7% equity of Youqi Intelligent for 130 million yuan [40] - Xinguo has submitted an application for H-share issuance and listing [42] - Jinhongshun's shareholder has terminated a share reduction plan [43] Group 10 - Wanrun Co.'s actual controller plans to increase shareholding between 365 million yuan and 730 million yuan [44] - Suzhou High-tech plans to sell 47% equity of its medical device subsidiary for 604 million yuan [45] - Huayou Cobalt's subsidiary has signed a product supply agreement with Yiwei Lithium Energy for approximately 127,800 tons of materials [47] Group 11 - China Communications has won 10 important projects totaling approximately 2.539 billion yuan [49] - Nopushin plans to raise no more than 1.45 billion yuan through a private placement [50] - Yun Aluminum plans to acquire minority stakes in three subsidiaries for a total of 2.267 billion yuan [51] Group 12 - Xiamen Tungsten plans to establish a 500 million yuan merger fund with multiple parties [52] - Aotewei has signed a contract worth approximately 700 million yuan [54] - Hemai Co.'s shareholders plan to reduce their holdings by no more than 3% [56]

| 证券代码：301098 | 证券简称：金埔园林 | 公告编号：2025-142 | | --- | --- | --- | | 债券代码：123198 | 债券简称：金埔转债 | | 金埔园林股份有限公司 关于公司涉及重大诉讼的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1.案件所处的诉讼阶段：法院已受理，尚未正式开庭 2.上市公司所处的当事人地位：原告 3.涉案的金额：2,655.70 万元 4.对上市公司损益产生的影响：因本案尚未正式开庭，目前暂时无法预计本 案对公司本期及期后利润的具体影响。公司将根据诉讼进展情况及时履行信息披 露义务，敬请广大投资者理性投资，注意投资风险。 一、本次诉讼受理的基本情况 金埔园林股份有限公司（以下简称"公司"或"原告"）于 2025 年 11 月 24 日收到淮安市淮阴区人民法院下发的《受理案件通知书》《交纳诉讼费用通 知书》【（2025）苏 0804 民初 11165 号】，诉讼受理的基本情况如下： （一）诉讼理由 2019 年 9 月 12 日，原告、被告一签订《徐溜镇涵洞村特色田园乡村（农民 ...

Core Insights - The company Jinpu Garden (301098) reported that as of November 20, 2025, the total number of registered shareholders in its combined ordinary and margin trading accounts is 10,816 [1] Summary by Categories - **Company Information** - Jinpu Garden has a total of 10,816 registered shareholders in its combined ordinary and margin trading accounts as of the specified date [1]

Core Points - Jinpu Garden (301098) announced the election of Liu Yanli as the employee representative director of the fifth board of directors during the employee representative meeting scheduled for November 17, 2025 [1] Company Summary - The company will hold an employee representative meeting on November 17, 2025 [1] - Liu Yanli has been elected as the employee representative director [1]

| 证券代码：301098 | 证券简称：金埔园林 | 公告编号：2025-140 | | --- | --- | --- | | 债券代码：123198 | 债券简称：金埔转债 | | 金埔园林股份有限公司 关于召开 2025 年第四次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 金埔园林股份有限公司（以下简称"公司"）于 2025 年 11 月 20 日召开第五 届董事会第二十九次会议，审议通过了《关于召开 2025 年第四次临时股东会的 议案》，公司决定于 2025 年 12 月 9 日（星期二）下午 15:00 以现场表决与网络 投票相结合的方式召开公司 2025 年第四次临时股东会（以下简称"股东会"）， 根据有关规定，现将会议的有关事项通知如下： 一、召开会议的基本情况 1.会议届次：2025 年第四次临时股东会 2.会议召集人：公司第五届董事会 3.会议召开的合法、合规性：本次股东会的召集程序符合《中华人民共和国 公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票上市规则》等 有关法律法规及《公司章程》的规定 4.会议 ...